Two Or More Phosphorus Atoms Directly Or Indirectly Bonded Together By Only Covalent Bonds Patents (Class 514/102)
  • Patent number: 10375961
    Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazolylisoxazoline of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 13, 2019
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Ulrike Wachendorff-Neumann, Sebastian Hoffmann, Pierre Wasnaire
  • Patent number: 10118881
    Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis H. Dasseux, Carmen D. Oniciu
  • Patent number: 9901589
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: February 27, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9895383
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9730875
    Abstract: Fragrances that provide a scent of freshness tend to be volatile and are therefore not very economical when used in typical applications such as washing or cleaning processes, so they have to be used in relatively large quantities to be able to produce adequate effects. The disclosed photolabile pro-fragrances provide a much longer-lasting sense of fragrance, in particular with a scent of freshness, when used in typical applications, thus allowing said fragrances to be used economically.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 15, 2017
    Assignee: Henkel AG & Co. KGaA
    Inventors: Thomas Gerke, Christian Kropf, Ursula Huchel, Axel Griesbeck, Agnieszka Landes
  • Patent number: 9694022
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: July 4, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9669040
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 6, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9655908
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid and neridronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 23, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9623037
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9624152
    Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: April 18, 2017
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis H. Dasseux, Carmen D. Oniciu
  • Patent number: 9511105
    Abstract: The present invention provides ointment, suppository, and herbal tea modalities for the treatment of hemorrhoids. The ointment and suppository modalities include the extracts of Nigella sativa, leek seed powder, Adeps camel, cow butter oil (Friesian), cow butter oil (Jersey), water buffalo butter oil, sheep butter oil, goat butter oil, coconut oil, and farm cow butter oil. The herbal tea modalities include Mentha piperita, Peppermint (American Mentha), Mentha aquatic, and Mentha longifolia (Moroccan mint).
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: December 6, 2016
    Inventor: Mohamed Jihath Mohammad Jamal Al Attar
  • Patent number: 9433675
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: September 6, 2016
    Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Patent number: 9416149
    Abstract: The invention provides methods for treating fibrosis, as well as methods for modulating mitochondrial peroxide production in a cell, and methods for modulating the import of Rac1 into the mitochondria of a cell.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: August 16, 2016
    Assignee: University of Iowa Research Foundation
    Inventors: Raymond J. Hohl, A. Brent Carter
  • Patent number: 9315531
    Abstract: Titanocene-gold compounds are provided that are useful for treating cancers.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 19, 2016
    Assignees: Research Foundation of the City University of New York, University of Hawaii
    Inventors: Maria Contel, Jacob Fernandez-Gallardo, Benelita T. Elie, Joe W. Ramos
  • Patent number: 9289385
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: March 22, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9289384
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: March 22, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9284261
    Abstract: Fragrances that provide a scent of freshness tend to be volatile and are therefore not very economical when used in typical applications such as washing or cleaning processes, so they have to be used in relatively large quantities to be able to produce adequate effects. The disclosed photolabile pro-fragrances provide a much longer-lasting sense of fragrance, in particular with a scent of freshness, when used in typical applications, thus allowing said fragrances to be used economically.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: March 15, 2016
    Assignee: Henkel AG & Co. KGaA
    Inventors: Thomas Gerke, Christian Kropf, Ursula Huchel, Axel Griesbeck, Agnieszka Landes
  • Patent number: 9216153
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: December 22, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9149487
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: October 6, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9150902
    Abstract: A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: October 6, 2015
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Koji Yamamoto, Kiyoshi Suzuki, Shuichi Miyaura
  • Patent number: 9068151
    Abstract: Fragrances having a fresh character are usually very volatile and therefore not very economical in typical applications such as washing or cleaning processes for example. For that reason they have to be used in relatively large amounts in order to bring about appropriate effects. The present invention describes photolabile pro-fragrances that allow for a greatly improved persistence of the fragrance impression, in particular one having a fresh character, in typical applications. A more economical use of the fragrances in question can be ensured in this way.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: June 30, 2015
    Assignee: Henkel AG & Co. KGaA
    Inventors: Thomas Gerke, Christian Kropf, Ursula Huchel, Axel Griesbeck, Olga Mayer
  • Patent number: 9056079
    Abstract: This invention provides derivatives of dodecapeptide ISSIKEKYPSHS (SEQ ID NO: 11) which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: June 16, 2015
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Galila Agam, Orna Almog, Itzchak Levi, Yael Eskira, Yuly Bersudsky
  • Publication number: 20150141374
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150141373
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150133403
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150119367
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: October 29, 2013
    Publication date: April 30, 2015
    Applicant: Allergan, Inc.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst
  • Publication number: 20150018316
    Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 15, 2015
    Inventor: Barbara Brooke Jennings
  • Patent number: 8895056
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 25, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Jr., Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F. A. Hossainy, Rachel Bright, Jeffrey Ellis
  • Patent number: 8883203
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Merrion Research III Limited
    Inventor: Thomas W. I. Leonard
  • Publication number: 20140296134
    Abstract: Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 2, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Tor Savidge, Sara Dann
  • Patent number: 8841281
    Abstract: The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: September 23, 2014
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventor: Joseph S. Merola
  • Publication number: 20140274966
    Abstract: A drink product having as an active ingredient genistein and an inositol hexaphosphate and/or an unphosphorylated inositol and optionally additional inositol (unphosphorylated as well as hexaphosphorylated) moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other 8 optical isomers thereof. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.
    Type: Application
    Filed: August 21, 2013
    Publication date: September 18, 2014
    Applicant: HYGIA PHARMACEUTICALS, LLC
    Inventor: Barbara Brooke Jennings
  • Publication number: 20140274965
    Abstract: A drink product having as an active ingredient an inositol hexaphosphate and optionally additional inositol moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other 8 optical isomers thereof. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: HYGIA PHARMACEUTICALS, LLC
    Inventor: Barbara Brooke Jennings
  • Publication number: 20140249105
    Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.
    Type: Application
    Filed: July 25, 2011
    Publication date: September 4, 2014
    Applicant: Diverchim
    Inventors: Jean-Louis Brayer, Natacha Frison, Benoit Folleas
  • Patent number: 8815227
    Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: August 26, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Publication number: 20140235590
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Patent number: 8778914
    Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 15, 2014
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Katrin Hochdoerffer
  • Patent number: 8772267
    Abstract: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: July 8, 2014
    Assignee: New York University
    Inventor: Marco Pappagallo
  • Publication number: 20140186471
    Abstract: The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 3, 2014
    Inventors: Anastasia Daifotis, Selwyn Aubrey Stoch, Basil Avery Ince, Cameron Black
  • Patent number: 8765674
    Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 1, 2014
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
  • Patent number: 8748410
    Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: June 10, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
  • Patent number: 8697124
    Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: April 15, 2014
    Assignee: Arrow International Limited
    Inventors: Peter Persicaner, Craig Judy
  • Publication number: 20140066407
    Abstract: The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula and the active compound of groups (1) to (24) listed in the description have very good fungicidal properties.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Bayer Intellectual Property GmbH
    Inventors: DUTZMANN Stefan, STENZEL Klaus, JAUTELAT Manfred
  • Publication number: 20130337022
    Abstract: A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent.
    Type: Application
    Filed: November 28, 2011
    Publication date: December 19, 2013
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Viness Pillay, Rubina Perveen Shaikh, Yahya Essop Choonara, Lisa Claire Du Toit
  • Publication number: 20130316991
    Abstract: The invention relates to dietary and prophylactic biologically active food supplements (BAS), in particular, from raw plant material and methods for their production; it can be used as a food supplement for human and domestic animals to reduce the cholesterol content in blood, stimulation of protein glycosylation and prophylaxis of infectious and cardiovascular diseases. The technical result of applying the BAS proposed consists in the creation of a drug for reducing the cholesterol content in blood, stimulation of protein glycosylation and prophylaxis of infectious and cardiovascular diseases. The biologically active supplement contains at least one polyprenyl phosphates or polyprenyl pyrophosphate with isoprene components from 7 to 30 or a mixture of different polyprenyl phosphates and polyprenyl pyrophospates adsorbed on a solid sorbent (sorbite, lactose, and starch) and also beta-sitosterin.
    Type: Application
    Filed: December 27, 2012
    Publication date: November 28, 2013
    Applicant: GAMAVETFARM LTD
    Inventor: GAMAVETFARM LTD
  • Publication number: 20130302448
    Abstract: A phytin aqueous solution including at least one alpha-hydroxylated carboxylic acid and phytin in a solubilized form, preferably in a concentration ranging from 70 g/L to 270 g/L, and in that it has a pH value ranging from 3 to 5. The phytin aqueous solution may be used in the preparation of a liquid nutritional supplement and in the preparation of a cosmetic composition.
    Type: Application
    Filed: May 10, 2012
    Publication date: November 14, 2013
    Inventor: Guy PARC
  • Publication number: 20130289621
    Abstract: A drug-impregnated sleeve for encasing a medical implant is provided. In one embodiment, the sleeve may include a body made of a biologically-compatible material that defines an internal cavity configured to receive the medical implant. In one embodiment, the biologically-compatible material is bioresorbable. The body may include a plurality of apertures, such as perforations or holes, extending from the cavity through the body. The sleeve may further include a first end, a second end, and a drug impregnated into the resorbable sheet. In one possible embodiment, the first end of the sleeve may be open for receiving the medical implant therethrough and the second end may be closed. The implant may be encased in the sleeve and implanted into a patient from which the drug is dispensed in vivo over time to tissue surrounding the implantation site.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 31, 2013
    Inventors: Mark T. Fulmer, David A. Armbruster, Robert Frigg, Elliot A. Gruskin, Sean H. Kerr
  • Publication number: 20130280286
    Abstract: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).
    Type: Application
    Filed: May 30, 2012
    Publication date: October 24, 2013
    Applicant: JOHANNES GUTENBERG-UNIVERSITAET MAINZ
    Inventors: Christoph VON EICHEL-STREIBER, Jessica REINEKE, Stefan TENZER, Hansjörg SCHILD, Maja RUPNIK
  • Patent number: 8524691
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 3, 2013
    Assignee: The Medicines Company
    Inventors: Evelyne Dietrich, Ranga Reddy, Kelly Tanaka, Ting Kang, Yanick LaFontaine, Adel Rafai Far
  • Patent number: 8497301
    Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: July 30, 2013
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu